No Mercy / No Malice: The Weight

The most transformative technology of our time isn't AI or rockets—it's GLP-1 weight-loss drugs. Scott Galloway argues that these medications, from Ozempic to Eli Lilly's new pill Foundeo, are not just shrinking waistlines but triggering a seismic shift across American society, from fast food to fashion and healthcare. With obesity rates peaking at 40% and now declining, GLP-1s are proving effective at reversing chronic disease networks, yet access remains wildly unequal. While Medicare will soon cover them for seniors at $50/month, private insurers are slashing coverage, demanding weigh-ins, meal tracking, and health coaching—essentially turning a life-saving tool into a bureaucratic hurdle. Galloway warns that the U.S. is simultaneously accelerating toward a healthier future while actively sabotaging it through rationing. The result? A rare case where capitalism actually works for consumers—because lowering prices increases demand—but only if we choose to distribute this miracle medicine widely. The real question isn't whether GLP-1s will change America. It already has. The question is whether we’ll be smart enough to let them.